Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Is gene array testing to be considered routine now?

Paik S.

Breast. 2011 Oct;20 Suppl 3:S87-91. doi: 10.1016/S0960-9776(11)70301-0. Review.

PMID:
22015300
2.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

3.
4.

[Gene expression based multigene prognostic and predictive tests in breast cancer].

Pénzváltó Z, Mihály Z, Gyorffy B.

Magy Onkol. 2009 Dec;53(4):351-9. doi: 10.1556/MOnkol.53.2009.4.4. Review. Hungarian.

5.

Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.

Ross JS.

Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Review.

PMID:
19546609
6.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
7.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

8.

Genomics of adjuvant therapy for breast cancer.

Kim SR, Paik S.

Cancer J. 2011 Nov-Dec;17(6):500-4. doi: 10.1097/PPO.0b013e31823e5370. Review.

PMID:
22157294
9.

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M.

Breast Cancer Res. 2008;10(4):R65. doi: 10.1186/bcr2124. Epub 2008 Jul 28.

10.

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.

Gevensleben H, Göhring UJ, Büttner R, Heukamp LC, Kunz G, Dimpfl T, Jackisch C, Ortmann O, Albert US, Bender R, De Snoo F, Krijgsman O, Glas AM, Ergönenc YH, Vogel C, Dykgers A, Langwieder C, Rees M, Anzeneder T.

Int J Mol Med. 2010 Dec;26(6):837-43.

PMID:
21042777
11.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
12.

Commercialized multigene predictors of clinical outcome for breast cancer.

Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN.

Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248. Review. Erratum in: Oncologist. 2008 Aug;13(8). doi: 10.1634/theoncologist.2007-0248.

13.

Impact of gene expression profiling tests on breast cancer outcomes.

Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, Goodman SN.

Evid Rep Technol Assess (Full Rep). 2007 Dec;(160):1-105. Review.

14.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
15.

A three-gene model to robustly identify breast cancer molecular subtypes.

Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C.

J Natl Cancer Inst. 2012 Feb 22;104(4):311-25. doi: 10.1093/jnci/djr545. Epub 2012 Jan 18.

16.

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS.

Ann Oncol. 2012 Dec;23(12):2997-3006. doi: 10.1093/annonc/mds586. Review.

17.

Molecular predictors of response to therapy for breast cancer.

Galanina N, Bossuyt V, Harris LN.

Cancer J. 2011 Mar-Apr;17(2):96-103. doi: 10.1097/PPO.0b013e318212dee3. Review.

PMID:
21427553
18.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
19.
20.

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.

Cancer Res. 2010 Nov 1;70(21):8852-62. doi: 10.1158/0008-5472.CAN-10-1039. Epub 2010 Oct 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk